Uremic Neurotoxin in the Middle Molecular Weight Range
1980; Wiley; Volume: 4; Issue: 2 Linguagem: Inglês
10.1111/j.1525-1594.1980.tb03916.x
ISSN1525-1594
AutoresN. K. Man, G Cueille, J. Zingraff, J. Boudet, A Sausse, J.L. Funck‐Brentano,
Tópico(s)Amyotrophic Lateral Sclerosis Research
ResumoABSTRACT Among the middle molecule fractions obtained by high performance gel chromatography on Sephadex G‐15 combined with gradient ion exchange chromatography on DEAE Sephadex A‐25 from plasma ultrafiltrates of six polyneuropathic patients, only peak b 4–2 was at a significantly higher concentration than that obtained from uremic patients with neuropathy. Purification of the b 4–2 solute allows its quantitative determination in biological fluids. The b 4–2 plasma concentrations are 1 mg/L in healthy subjects (n=30), 4.6 ± 0.2 mg/L in uremic patients (n=67) and 13–19 mg/L in six polyneuropathic patients. The 24‐hr urinary excretion is 13 ± 1 mg. The weekly removal rates in hemofiltration or in hemodialysis, using high permeability membrane three times a week, are 38–40 mg. In an in vitro sural nerve test for the evaluation of middle molecule neurotoxicity, the b 4–2 solute exhibits a neurotoxic effect at concentrations similar to those found in plasma of neuropathic patients. Preliminary results of an attempt to identify the neurotoxin indicate that it is an acid‐polyo derivative.
Referência(s)